Clinical Trial

Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Name: Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia — clinical trial record (NCT07690891)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label Phase 2 study designed to evaluate the treatment outcomes of nemtabrutinib-venetoclax-obinutuzumab as a frontline management for chronic lymphocytic leukemia (CLL).

Trial Details

NCT Number	NCT07690891
Lead Sponsor	Medical College of Wisconsin
Conditions	Chronic Lymphocytic Leukemia
Enrollment	30 participants
Start Date	2026-10-01
Primary Completion	2029-12-01 (estimated)
Study Completion	2031-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-08